Investor Relations
Stock Information
| Ticker | SNTS |
| Exchange | NASDAQ |
| Price | $5.80 |
| Change | - 0.45 |
| Volume | 888,600 |
| May 17, 2012 4:00 PM ET | |
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company’s current commercial efforts are focused on GLUMETZA® (metformin hydrochloride extended release tablets) and CYCLOSET® (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes, and on FENOGLIDE® (fenofibrate) tablets, which is indicated as an adjunct to diet to reduce high cholesterol.
Santarus has a diverse product development pipeline. A New Drug Application for UCERIS™ (budesonide) tablets for induction of remission of mild to moderate active ulcerative colitis is under review by the U.S. Food and Drug Administration with a response expected in October 2012. The pipeline also includes two late-stage investigational drugs: RHUCIN® (recombinant human C1 inhibitor) for treatment of acute attacks of hereditary angioedema and rifamycin SV MMX® for treatment of travelers’ diarrhea, both of which are being evaluated in Phase III clinical studies. In addition, the company’s investigational monoclonal antibody, SAN-300, is being evaluated in a Phase I clinical program.
Recent Releases
May 18, 2012
Santarus Announces Presentation of UCERIS Phase III Extended Use Data at Digestive Disease Week Meeting
May 8, 2012
Santarus Reports First Quarter 2012 Financial Results
May 7, 2012
Santarus to Present at Bank of America Merrill Lynch 2012 Health Care Conference
Events & Presentations
There are no upcoming events at this time.
